人源性长寿保障基因2在结直肠癌组织中的表达及其临床意义

doi:10.6040/j.issn.1671-7554.0.2019.180

摘要/Abstract

摘要： 目的探讨人源性长寿保障基因2(LASS2)在结直肠癌组织中的表达及其临床意义。方法选取2011年8月至2013年8月结直肠癌患者85例,免疫组化(SP法)检测结直肠癌和癌旁组织中LASS2蛋白表达,术后随访,随访截止日期为2018年8月30日,78例患者得到完整随访,随访率91.76%。生存分析采用Kaplan-Meier法和Log-rank检验,患者预后的影响因素分析采用Cox比例风险回归模型。结果 LASS2蛋白在结直肠癌组织中阳性表达率(32.94% vs 78.82%,P<0.001)低于癌旁组织。LASS2蛋白在中低分化、TNM分期Ⅲ+Ⅳ期和发生淋巴结转移的结直肠癌组织中阳性表达率低于高分化、TNM分期Ⅰ+Ⅱ期和未发生淋巴结转移的结直肠癌组织(P<0.05);LASS2蛋白阳性表达组患者总生存时间(57.60个月 vs 28.47个月, P<0.001)及累积生存率(55.60% vs 19.60%,P<0.001)高于LASS2蛋白阴性表达组。分化程度、TNM分期、淋巴结转移和LASS2蛋白表达是影响结直肠癌患者预后的风险因素(HR=0.134、2.907、2.478、0.476,P<0.05)。结论 LASS2蛋白在结直肠癌患者组织中呈低表达,且与患者恶性化进展及预后有关,可能是结直肠癌患者预后评估的潜在生物标志物。

关键词: 结直肠癌, 人源性长寿保障基因2, 预后, Cox比例风险回归模型

Abstract: Objective To investigate the expression and clinical significance of homo sapiens longevity assurance homologue 2 of yeast LAG1(LASS2)in colorectal cancer. Methods A total of colorectal cancer 85 cases treated during Aug. 2011 and Aug. 2013 were involved. The protein expression of LASS2 in colorectal cancer and adjacent tissues were detected with immunohistochemistry(SP method). All patients were followed up, and until Aug. 30, 2018, the complete follow-up data of 78(91.76%)cases were obtained. Patients’ survival was analyzed using Kaplan-Meier method and Log-rank test. The influencing factors on prognosis were determined with Cox proportional hazards regression model. Results The positive expression rates of LASS2 in colorectal cancer tissues and adjacent tissues was 32.94% vs 78.82%(P<0.001). The positive expression rates of LASS2 in colorectal cancer tissues with moderately poor differentiation, TNM stage Ⅲ+Ⅳ and lymph node metastasis were lower than that in high differentiation, TNM stage Ⅰ+Ⅱ and without lymph node metastasis(P<0.05). The overall survival of patients with positive versus negative LASS2 expression was 57.60 vs 28.47 months(P<0.001), and cumulative survival rate was 55.60% vs 19.60%(P<0.001). The differentiation, TNM stage, lymph node metastasis and protein expression of LASS2 were influencing factors on the 山东大学学报 (医学版)57卷7期 -郭艳,等.人源性长寿保障基因2在结直肠癌组织中的表达及其临床意义 \=-prognosis(HR=0.134, 2.907, 2.478 and 0.476, P<0.05). Conclusion LASS2 is lowly expressed in colorectal cancer tissues, and is related to the malignant progression and prognosis. It might be a potential biomarker for prognosis assessment.

Key words: Colorectal cancer, Homo sapiens longevity assurance homologue 2 of yeast LAG1, Prognosis, Cox proportional hazard regression model

中图分类号:

R735.3

郭艳,张哲莹,王云溪,魏小娟. 人源性长寿保障基因2在结直肠癌组织中的表达及其临床意义[J]. 山东大学学报 (医学版), 2019, 57(7): 67-71.

8.GUO Yan, ZHANG Zheying, WANG Yunxi, WEI Xiaojuan. Expression and clinical significance of homo sapiens longevity assurance homologue 2 of yeast LAG1 in colorectal cancer[J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 67-71.

参考文献

[1] Murphy CC, Wallace K, Sandler RS, et al. Racial disparities in incidence of young-onset colorectal cancer and patient survival [J]. Gastroenterology, 2019, 156(4): 958-965.
[2] Pang QY, An R, Liu HL. Perioperative transfusion and the prognosis of colorectal cancer surgery: a systematic review and meta-analysis [J]. World J Surg Oncol, 2019, 17(1): 7-13.
[3] 刘童, 张欣, 王传新. IRX5 mRNA在结直肠癌诊断及预后中的价值[J]. 山东大学学报(医学版), 2016, 54(7): 69-74, 87. LIU Tong, ZHANG Xin, WANG Chuanxin. Significance of IRX5 mRNA in the diagnosis and prognosis of colorectal cancer [J]. Journal of Shandong University(Health Sciences), 2016, 54(7): 69-74, 87.
[4] 张静, 王晰程, 沈琳. 分子标志物对Ⅱ期和Ⅲ期结直肠癌术后随访策略的影响[J]. 中华胃肠外科杂志, 2018, 21(6): 716-720. ZHANG Jing, WANG Xicheng, SHEN Lin. Impacts of microsatellite status, RAS and BRAF mutation on postoperative follow-up strategy in stage Ⅱ and Ⅲ colorectal cancer [J]. Chinese Journal of Gastrointestinal Surgery, 2018, 21(6): 716-720.
[5] Yegin Z, Aydin O, Koc H, et al. Expression profiles of proto-oncogene TWIST1 and tumor metastasis suppressor gene LASS2 in bladder cancer [J]. Cell Mol Biol(Noisy-le-grand), 2018, 64(11): 66-73.
[6] 左华楚, 李秀霞, 李时荣, 等. LSAA2/TMSG-1基因沉默对人肺癌95C细胞侵袭迁移机制探讨[J]. 中华肿瘤防治杂志, 2015, 22(24): 1865-1873. ZUO Huachu, LI Xiuxia, LI Shirong, et al. Effect of LASS2/TMSG on the invasion and migration of 95C human pulmonary carcinoma cell [J]. Chinese Journal of Cancer Prevention and Treatment, 2015, 22(24): 1865-1873.
[7] 王鑫, 王忠臣, 孙微微. 血管生成素样蛋白1在结直肠癌中表达的意义及对其生物学行为的影响[J]. 中华普通外科杂志, 2018, 33(4): 326-329. WANG Xin, WANG Zhongchen, SUN Weiwei. Clinicopathological significance and biological behavior of ANGPTLl expression in human colorectal cancer [J]. Chinese Journal of General Surgery, 2018, 33(4): 326-329.
[8] Zhang S, Yang Y, Yan D, et al. Internet videos and colorectal cancer in mainland China: a content analysis [J]. BMC Med Inform Decis Mak, 2018, 18(1): 129-137.
[9] Ott C, Gerken M, Hirsch D, et al. Advanced mucinous colorectal cancer: epidemiology, prognosis and efficacy of chemotherapeutic treatment [J]. Digestion, 2018, 98(3): 143-152.
[10] Gan T, Sinner HF, Walling SC, et al. Impact of the affordable care act on colorectal cancer screening, incidence, and survival in Kentucky [J]. J Am Coll Surg, 2019, 228(4): 342-353.
[11] 刘铭, 王崑, 包全, 等. 肝转移灶个数对结直肠癌肝转移患者术后生存的影响[J]. 中华普通外科杂志, 2018, 33(1): 34-37. LIU Ming, WANG Kun, BAO Quan, et al. Effect of tumor number on the survival of patients of colorectal cancer liver metastases undergoing hepatic resection [J]. Chinese Journal of General Surgery, 2018, 33(1): 34-37.
[12] 朱宇, 王宏洁, 韩彬彬, 等. 人异常凝血酶原(PIVKA-II)在监测结直肠癌肝转移中的应用[J]. 山东大学学报(医学版), 2018, 56(10): 58-63. ZHU Yu, WANG Hongjie, HAN Binbin, et al. A study of serum PIVKA-II in patients with liver metastasis of colorectal cancer [J]. Journal of Shandong University(Health Sciences), 2018, 56(10): 58-63.
[13] Kim H, Jung HI, Kwon SH, et al. Preoperative neutrophil-lymphocyte ratio and CEA is associated with poor prognosis in patients with synchronous colorectal cancer liver metastasis [J]. Ann Surg Treat Res, 2019, 96(4): 191-200.
[14] Wang H, Zuo Y, Ding M, et al. LASS2 inhibits growth and invasion of bladder cancer by regulating ATPase activity [J]. Oncol Lett, 2017, 13(2): 661-668.
[15] Mei F, You J, Liu B, et al. LASS2/TMSG1 inhibits growth and invasion of breast cancer cell in vitro through regulation of vacuolar ATPase activity [J]. Tumour Biol, 2015, 36(4): 2831-2844.
[16] Fan SH, Wang YY, Wu ZY, et al. AGPAT9 suppresses cell growth, invasion and metastasis by counteracting acidic tumor microenvironment through KLF4/LASS2/V-ATPase signaling pathway in breast cancer [J]. Oncotarget, 2015, 6(21): 18406-18417.
[17] Zou P, Yang Y, Xu X, et al. Silencing of vacuolar ATPase c subunit ATP6V0C inhibits the invasion of prostate cancer cells through a LASS2/TMSG1-independent manner [J]. Oncol Rep, 2018, 39(1): 298-306.
[18] Yang Y, Yang X, Li L, et al. LASS2 inhibits proliferation and induces apoptosis in HepG2 cells by affecting mitochondrial dynamics, the cell cycle and the nuclear factor?κB pathways [J]. Oncol Rep, 2019, 41(5): 3005-3014.
[19] 袁远, 黄恩应, 陈小刚. LASS2在膀胱癌组织中的表达及对细胞增殖和侵袭能力的影响[J]. 福建医科大学学报, 2018, 52(5): 311-315.
[20] 李时荣, 伊日贵, 左华楚, 等. 人类长寿保障基因2/肿瘤转移抑制基因1基因过表达对人肺癌细胞的影响[J]. 中华实验外科杂志, 2017, 34(7): 1252-1253. LI Shirong, YI Rigrui, ZUO Huachu, et al. Effects of homo sapiens longevity assurance homologue 2/tumor metastasis suppressor gene 1 gene overexpression on human lung cancer cells [J]. Chinese Journal of Experimental Surgery, 2017, 34(7): 1252-1253.
[21] Wang H, Zuo Y, Ding M, et al. LASS2 inhibits growth and invasion of bladder cancer by regulating ATPase activity [J]. Oncol Lett, 2017, 13(2): 661-668.
[22] Gu D, Jin H, Jin G, et al. The asialoglycoprotein receptor suppresses the metastasis of hepatocellular carcinoma via LASS2-mediated inhibition of V-ATPase activity [J]. Cancer Lett, 2016, 379(1): 107-116.
[23] Ke RH, Wang Y, Mao Y, et al. Decreased expression of LASS2 is associated with worse prognosis in meningiomas [J]. J Neurooncol, 2014, 118(2): 369-376.
[24] Ruan H, Wang T, Yang C, et al. Co-expression of LASS2 and TGF-β1 predicts poor prognosis in hepatocellular carcinoma [J]. Sci Rep, 2016, 6(9): 1-9.
[25] Sheng N, Wang Y, Xie Y, et al. High expression of LASS2 is associated with unfavorable prognosis in patients with ovarian cancer [J]. J Cell Physiol, 2019, 234(8): 13001-13013.

相关文章 15

[1]	郑苏,陈述花,李华,邓劼,陈春红,王晓慧,冯卫星,韩萧迪,张雨佳,李娜,李莫,方方. 脑电变化和BASED评分与54例婴儿痉挛症促肾上腺皮质激素疗效的相关性[J]. 山东大学学报 (医学版), 2022, 60(9): 91-96.
[2]	王丽慧,高敏,孔北华. 子宫血管肉瘤2例报告并文献复习[J]. 山东大学学报 (医学版), 2022, 60(9): 108-112.
[3]	高中霞,张铭,樊明德,谭晨阳,王梦迪,王超,樊跃飞,丁守銮,王成伟. 伽玛刀治疗81例肺癌脑转移瘤的疗效及预后因素[J]. 山东大学学报 (医学版), 2022, 60(8): 44-49.
[4]	贺士卿,李皖皖,董书晴,牟婧怡,刘宇莹,魏思雨,刘钊,张家新. 基于数据库构建乳腺癌焦亡相关基因的预后风险模型[J]. 山东大学学报 (医学版), 2022, 60(8): 34-43.
[5]	张玉凤,徐敏,邢秀丽,逄曙光,户克庆. 689例非ST段抬高型心肌梗死患者的临床流行病学特征[J]. 山东大学学报 (医学版), 2022, 60(7): 118-122.
[6]	李琳琳,王凯. 基于生物信息学预测肝细胞癌预后基因[J]. 山东大学学报 (医学版), 2022, 60(5): 50-58.
[7]	郑昊天,王光辉,赵小刚,王亚东,曾榆凯,杜贾军. 基于数据库LKB1突变肺腺癌DNA异常甲基化位点构建的预后风险模型[J]. 山东大学学报 (医学版), 2022, 60(3): 51-58.
[8]	陈立晓,英信江,陈歆维,王菲,孙臻峰,董频. 下咽鳞癌蛋白质谱鉴定及预后靶分子筛选[J]. 山东大学学报 (医学版), 2021, 59(9): 140-147.
[9]	褚晏,刘端瑞,朱文帅,樊荣,马晓丽,汪运山,郏雁飞. DNA甲基化转移酶在胃癌中的表达及其临床意义[J]. 山东大学学报 (医学版), 2021, 59(7): 1-9.
[10]	陈丽宇,肖娟,吕仙忠,段宝敏,洪凡真. 影响孕产妇下肢深静脉血栓预后的危险因素分析[J]. 山东大学学报 (医学版), 2021, 59(7): 38-42.
[11]	田瑶天,王宝,李叶琴,王滕,田力文,韩波,王翠艳. 基于可解释性心脏磁共振参数的机器学习模型预测儿童心肌炎的预后[J]. 山东大学学报 (医学版), 2021, 59(7): 43-49.
[12]	李皖皖,周文凯,董书晴,贺士卿,刘钊,张家新,刘斌. 利用数据库信息构建乳腺癌免疫关联lncRNAs风险评估模型[J]. 山东大学学报 (医学版), 2021, 59(7): 74-84.
[13]	孙富云,王维鹏,张会会,耿艳,安小霞,李双双,张彬彬. 结直肠癌术后患者人格特质与抑郁、焦虑症状的关联性[J]. 山东大学学报 (医学版), 2021, 59(7): 91-96.
[14]	米琦,史爽,李娟,李培龙,杜鲁涛,王传新. 膀胱癌circRNAs介导的ceRNA网络及预后评估模型的构建[J]. 山东大学学报 (医学版), 2021, 59(6): 94-102.
[15]	谢同辉,陈志强,常建华,赵丹文,徐博文,智绪亭. 肝内胆管癌根治性切除术后生存因素分析及列线图的建立[J]. 山东大学学报 (医学版), 2021, 59(4): 93-99.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed